Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery

Author(s): Ulrich Wullner, Inga Neef, Mehmet K. Tur, Stefan Barth.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 4 , Issue 1 , 2009

Submit Manuscript
Submit Proposal

Abstract:

RNA interference (RNAi) is a powerful endogenous process initiated by short double stranded RNAs, which results in sequence-specific posttranscriptional gene silencing. The ability to block the expression of any disease-causing or disease-related protein emphasizes the huge therapeutic potential of this technology. In a clinical setting, however, the use of RNAi-based therapeutics is limited by their short serum half lives and poor uptake into cells. In this review, we provide an overview of recent patents in the field of short interfering RNA (siRNA) delivery and discuss recent progress in the development of efficient siRNA delivery vehicles enhancing the pharmacokinetic properties of RNAi-based therapeutics and promoting cellular uptake.

Keywords: RNA interference, specific knock-down, non-targeted delivery, targeted delivery, cell-specific ligands

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 4
ISSUE: 1
Year: 2009
Page: [1 - 8]
Pages: 8
DOI: 10.2174/157489209787002506

Article Metrics

PDF: 9